News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
News Cellular Intelligence scoops up Novo's Parkinson's therapy Novo Nordisk has sold the rights to one of the flagship candidates in its now-defunct cell therapy unit to AI start-up Cellular Intelligence.
News UCB cuts $1.15bn deal to buy epilepsy biotech Neurona UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Oncology Engineering “smarter” cells, with Tim Lu Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone
News Galapagos abandons cell therapy, putting 365 jobs at risk Galapagos' difficult year has continued with a decision to wind down its cell therapy business as it seeks 'transformative' deals for its drugs unit.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.